ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2125

Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study

Okinori Murata1, Atsuko Kudo2 and Katsuya Suzuki3, 1Department of Pulmonary medicine, Hachinohe Red Cross Hospital, Hachinohe, Japan, 2Hachinohe Red Cross Hospital, Hachinohe, Japan, 3Division of Rheumatology, Department of Internal Medicine, Keio University School of Medcine, Tokyo, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: lymphocytes, prognostic factors and sarcoidosis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarcoidosis is a systemic granulomatous disease that can affect multiple organs, and in particular lung involvements are common and found in more than 90% of the patients [1]. Spontaneous remission is often observed within 2 years [2] and chest radiographic stage, skin involvements, over 40 years old or smoking history are reported as poor prognostic factors in pulmonary salcoidosis [3, 4]. However, there were no comprehensive reports of factors of relapse or exacerbation and characteristics of favorable patients without treatment in the long-term period more than 2 years. Aim of study is to identify prognostic factors for relapse or exacerbation in patients with pulmonary sarcoidosis in the long-term period.

Methods: Ninety-three patients who had visited at our division of Hachinohe Red Cross Hospital between January 2007 and December 2016 and clinically diagnosed as pulmonary sarcoidosis, were enrolled. They were divided into two groups, which presented relapse or exacerbation, and spontaneous remission. Clinical, laboratory and imaging data were collected from medical records and statistically analyzed.

Results: In 93 patients, 77% were women and mean age at diagnosis was 50.1 ± 16.6 years old. Mean observation period was 9.9 ± 8.8 years. Numbers of patients who had previously reported short-term prognostic factors are following: chest radiographic stage (Stage 0: n=3, Stage Ⅰ: n=29, Stage Ⅱ: n=36, Stage Ⅲ: n=15, Stage Ⅳ: n=10), skin involvement (n=9), age over 40 years old (n=66), and smoking history (n=31). Overall relapse or exacerbation rate was 18.3% (n=17) and mean period to relapse or exacerbation was 8.5 ± 8.4 years. Then, we purified 64 patients who were observed for more than 5 years, and relapse or exacerbation was found in 7 patients. When compared characteristics at diagnosis between two groups, decrease of peripheral number of lymphocytes, frequency of bilateral hilar lymphadenopathy, or less than 3.5 in the ratio of CD4/CD8 in bronchoalveolar lavage fluid (BALF) were significantly highlighted in relapse or exacerbation group (P=0.019, 0.042, and 0.018, respectively).

Conclusion: Our long-term observational cohort study identified incidence rate and unique prongostic factors of relapse or exacerbation in patients with pulmonary sarcoidosis. This information could contibute to more appropriate medical administration in long term period.

References: [1] Br. J. Dis. Chest. 1976; 70:206–210, [2] Dan. Bull. Med. 1982; 29:27–32, [3] Br. Med. J. 1961; 2:1165–1172, [4] Chest. 2006; 130:1851-6.


Disclosure: O. Murata, None; A. Kudo, None; K. Suzuki, None.

To cite this abstract in AMA style:

Murata O, Kudo A, Suzuki K. Identification of Long-Term Prognostic Factors for Relapse or Exacerbation in Patients with Pulmonary Sarcoidosis: A Single Center Long-Term Observational Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identification-of-long-term-prognostic-factors-for-relapse-or-exacerbation-in-patients-with-pulmonary-sarcoidosis-a-single-center-long-term-observational-cohort-study/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-long-term-prognostic-factors-for-relapse-or-exacerbation-in-patients-with-pulmonary-sarcoidosis-a-single-center-long-term-observational-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology